A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors (MAST)

Neuroendocrine Neoplasms are considered solid tumours.

Imugene Limited, a clinical-stage immuno-oncology company, and City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced that the first patient was dosed in Phase 1 clinical trial evaluating the safety of novel cancer-killing virus CF33-hNIS VAXINIA when used in people with advanced solid tumors. The City of Hope-developed oncolytic virus has been shown to shrink colon, lung, breast, ovarian and pancreatic cancer tumors in preclinical laboratory and animal models.

Interestingly, the principal investigator is listed as a NET Specialist. No conclusions should be drawn from this knowledge, and I have no information to suggest that Neuroendocrine patients are included in the patient population of 100 for this trial.  The trial is being carried out in 3 US locations so far:  City of Hope Duarte, California, Next Oncology, Fairfax, Virginia and Barbara Ann Karmanos Cancer Institute, Detroit, Michigan. Additional clinical sites will be opened across the U.S. in 2022 – keep checking amendments to the clinical trials document linked below. Recruitment commenced Apr/May 2022, primary completion date of December 2024.

The clinical trial (NCT05346484) is here to read – click here.  As always, the exclusion and inclusion criteria are important.  Also read more here